Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.
Also called NCT02062645
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 115 participants
- Sponsor
- Registry
-
NCT02062645
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02062645. Allocation not applicable; no masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2017-03-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
- Condition
- Essential Hypertension
- Intervention (Drug)
- amlodipine/valsartan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02062645- Content hash
93fd9c861f18381746a8ac85f24de7af19ddf49986d012768fbef20811cafcde